Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Cutaneous T-cell Lymphoma Clinical Trial

Official title:

Sintilimab Combined With Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Single Arm Phase II Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04296786
• Other study ID #: PUMCH-NHL-006
• Status: Recruiting
• Phase: Phase 2
• Start date: November 1, 2019
• Est. completion date: December 2024

Study information

• Verified date: January 2020
• Source: Peking Union Medical College Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of Sintilimab combined with Chidamide in the treatment of relapsed/refractory cutaneous T-cell lymphoma.

Description:

This is a single-arm phase 2 study with fixed does of combined Sintilimab and Chidamide regimen. This regimen is repeated every 21 days. Sintilimab (200mg) is administered intravenously on day 1 of every cycle. Chidamide is used 20mg twice per week continuously. From the beginning of the trial, sindilimab will be used for 96 weeks, until disease progress, intolerable toxicity or patient/investigator discretion. Patients will continue to receive Chidamide treatment until disease progression, unacceptable toxicity, or patient/investigator discretion.

The response will be evaluated every 2 cycles in the first 36 weeks and every 4 cycles from week 36 till the end of treatment. The patients who achieve complete remission (CR), partial remission (PR), and stable disease (SD) will receive further treatment. The patients with progressed disease (PD) will be continue on the treatment and reassess after 4-8 weeks to rule out false progression. On confirmation of PD , patients will be withdrawn from the trial and receive salvage regimens.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: December 2024
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Pathologically confirmed cutaneous T-cell lymphoma according World Health Organization (WHO) classification.

• ECOG=2

• Patients with measurable lesions, with or without extra-dermal lesions, clinical stage of IIB-IVB.

• Patients received at least one systemic treatment previously and achieved no remission or relapsed after first-line treatment.

• Absolute neutrophil count (ANC)=0.75×109/L,platelet (PLT) = 50×109/L,hemoglobin (HGB)= 80 g/L

• Thyroid stimulating hormone (TSH) within normal range

Exclusion Criteria:

• Pre-existing uncontrolled active infection

• Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN), total bilirubin (TBIL) >1.5 times ULN, serum creatinine >1.5 times ULN

• Patients with clinically significant QT interval prolongation (male > 450ms, female > 470ms), ventricular tachycardia (VT), atrial fibrillation (AF), acute coronary syndrome (ACS) within 1 year, congestive heart failure (CHF), and symptomatic coronary heart disease.

• Patients who have received organ transplantation or hematopoietic stem cell transplantation.

• Active bleeding or recent thrombotic disease

• Patients with known interstitial lung disease

• Patients with active autoimmune disease or history of autoimmune disease in the past 2 years

• Patients with CNS involvement

• Pregnant or lactating women

• History of mental illness

Related Conditions & MeSH terms

• Cutaneous T-cell Lymphoma
• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Cutaneous

Intervention

Drug:
• Sintilimab
200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
• Chidamide
20mg po per week continuously

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (4)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital	Beijing Longfu Hospital, Dongzhimen Hospital, Beijing, Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	ORR was defined as the proportion of patients who achieved CR or PR as their best response.	From date of signing the informed consent until the date of first confirmed progression or date of death from any cause, whichever came first, assessed up to 104 weeks
Secondary	Adverse Events	Graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0	From date of signing the informed consent until the date of first confirmed progression or date of death from any cause, whichever came first, assessed up to 104 weeks
Secondary	Duration of response (DOR)	DOR was defined as the time from the first occurrence of CR or PR to the first diagnosis of PD or relapse.	From date of signing the informed consent until the date of first confirmed progression or date of death from any cause, whichever came first, assessed up to 104 weeks
Secondary	Progression-Free Survival (PFS)	PFS was defined as interval from patient enrollment to the date of disease progression or death from any cause.	PFS was defined as interval from patient enrollment to the date of disease progression or death from any cause, whichever came first, assessed up to 104 weeks